milademetan
Small moleculeexperimental
Clinical trial activity
13 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01877382)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 2
- Adrenocortical Carcinoma · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Gene Amplification · Phase 2
- Genes, p16 · Phase 1/Phase 2
- Heart Diseases · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Liposarcoma · Phase 3
- Lymphoma · Phase 1
- Melanoma · Phase 2
- Mesothelioma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pharmacokinetics · Early Phase 1
- Sarcoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Testicular Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- p53-binding protein Mdm-2INHIBITOR
MDM2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CCC2(CC1)N[C@@H](C(=O)N[C@@H]1CC[C@@H](C(N)=O)OC1)[C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc21- Mol. weight
- 618.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314415 ↗
- ChEMBLCHEMBL5314414 ↗
- ChEMBLCHEMBL4297374 ↗
- ChEMBLCHEMBL4292264 ↗
Also known as
- ds-3032b
- ds-3032b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05932667 | Phase 2 | Oct 12, 2023 | Curie Institute, Rain Oncology Inc |
| NCT06090318 | Phase 1/Phase 2 (Phase 2) | May 19, 2023 | Rain Oncology Inc |
| NCT05758818 | Phase 1 | Apr 17, 2023 | Rain Oncology Inc |
| NCT05012397 | Phase 2 | Nov 1, 2021 | Rain Therapeutics Inc. |
| NCT04979442 | Phase 3 | Jul 14, 2021 | Rain Therapeutics Inc. |
| NCT03634228 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03552029 | Phase 1 | Aug 27, 2018 | Daiichi Sankyo |
| NCT03671564 | Phase 1 | Aug 23, 2018 | Daiichi Sankyo |
| NCT03647202 | Early Phase 1 (Phase 1) | Aug 16, 2018 | Daiichi Sankyo |
| NCT03614455 | Early Phase 1 (Phase 1) | Jul 13, 2018 | Daiichi Sankyo |
| NCT02579824 | Phase 1 | Aug 1, 2016 | Daiichi Sankyo, University of Texas at Houston |
| NCT02319369 | Phase 1 | Nov 1, 2014 | Daiichi Sankyo |
| NCT01877382 | Phase 1 | Jul 1, 2013 | Daiichi Sankyo |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 7 | 6 | 1 | 2013 |
| Rain Oncology Inc | For profit | 3 | 2 | 2 | 2023 |
| Rain Therapeutics Inc. | For profit | 2 | 2 | 2 | 2021 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Curie Institute | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1